“GT is a fascinating evolutionary phenomenon observed in lower species and humans, albeit with differing impacts and mechanisms.”

BUFFALO, NY - August 09, 2024 – A new editorial was published in Oncoscience (Volume 11) on July 13, 2024, entitled, “Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization.”

The complex interplay between extracellular genetic material and the tumor's genetic landscape presents a significant challenge in grasping cancer evolution,

“In this research perspective, we review the current state of chemoprevention and cancer interception progress in asbestos-induced mesothelioma.”

BUFFALO, NY - July 19, 2024 – A new research perspective was published in Oncoscience (Volume 11) on May 23, 2024, entitled, “Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma.”

In this perspective, researchers Joseph R. Testa, Yuwaraj Kadariya, and Joseph S. Friedberg from Fox Chase

“We are optimistic that the incorporation of ADCs into the treatment of aggressive tumors and treatment refractory gynecologic cancers will improve quality of life and survival outcomes in our patients.”

BUFFALO, NY - July 12, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Entering the golden age for antibody-drug conjugates in gynecologic cancer.”

In this new editorial, researchers Michelle Greenman, Blair McNamara, Levent Mutlu, and

“The deployment of DL segmentation methods in 18F-fluciclovine PET/CT imaging represents an intriguing research direction for precision medicine in salvage prostate cancer care.”

BUFFALO, NY - June 28, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation therapy in prostate cancer.”

In this new editorial, researchers Richard L.J. Qiu, Chih

“[...] PHA is a rare yet aggressive mesenchymal tumor of the liver, which requires a multi-disciplinary approach to achieve the best patient outcomes.”

BUFFALO, NY - June 21, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Primary hepatic angiosarcoma: Treatment options for a rare tumor.”

In this new editorial, researchers Gregory L. Guzik and Ankit Mangla from University Hospitals Cleveland Medical Center, University Hospitals Seidman

“Elucidating the function of Erk5 in cancer [...] will contribute to a better understanding of cancer pathogenesis and the development of novel therapeutic strategies.”

BUFFALO, NY - June 14, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Role of Erk5 expressed in bone marrow mesenchymal stem cells on bone homeostasis and its potential applications in cancer treatment.”

In their new editorial, researchers Tetsuhiro Horie and Eiichi

“Impact Journals (Oncoscience's publisher) is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer Center in Buffalo, New York.”

BUFFALO, NY- June 11, 2024 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New

“[...] the identification of ubiquitin-conjugating enzymes like UBE2J1 and the innovative deployment of PROTAC-type androgen receptor degraders are crucial in combating prostate cancer and overcoming therapeutic resistance.”

BUFFALO, NY - June 7, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on May 6, 2024, entitled, “Restoring our ubiquitination machinery to overcome resistance in cancer therapy.”

In this new editorial, researchers Xiaoling Li and Ping Mu from

“We have identified binding motifs within the C-tails of PAR_1,2&4, indispensable for cancer growth and development.”

BUFFALO, NY - May 24, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs.”

While targeted cancer therapy is greatly dependent on specific oncogenic pathways or conferred by genetic alterations, it remains yet challenging and

“The advancement of novel therapies like CAR-T in relapsed and refractory pediatric B-ALL is truly a beacon of hope for children and young adults with a previously dismal prognosis.”

BUFFALO, NY - May 17, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “The price of hope: CAR-T therapy in pediatric leukemia.”

We stand at the crossroads of medical innovation, where cutting-edge scientific discoveries intersect with the resilience of

BUFFALO, NY- May 13, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncoscience is one of the most prominent journals published by Impact Journals.

Impact Journals is proud to participate as an exhibitor at the Society for Scholarly Publishing (SSP) 46th Annual Meeting, which convenes in Boston, Massachusetts, at the Westin Boston Seaport District from May 29–31, 2024. This year, the SSP Annual

“These results argue that combinations based on immunotherapy may also provide an opportunity for targeting urothelial cancers with low TMB, and provide efficacy superior to classic chemotherapy.”

BUFFALO, NY - May 10, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy.”

In this new editorial, researcher Ioannis A. Voutsadakis from Sault Area Hospital

“[...] this editorial underscores the complex molecular diagnosis landscape of cancer in the [Latin American] population.”

BUFFALO, NY - May 03, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 22, 2024, entitled, “Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for enhanced molecular understanding.”

In this editorial, researcher Rafael Parra-Medina from Fundación Universitaria de Ciencias de la Salud

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncoscience is one of the most prominent journals published by Impact Journals.

Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring

“Given that the MET inhibitor capmatinib caused a remarkable response in Dr. Blagosklonny, a pertinent question remains as to why he was not treated with ‘preemptive drug combinations’ [...]”

BUFFALO, NY - February 23, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on February 9, 2024, entitled, “A very long and winding road: developing novel therapeutics for metastatic tumors.”

In this editorial, researcher Paul Dent from the Department of Biochemistry and

“This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the current standard current first line chemotherapy for pancreatic ductal adenocarcinoma (PDAC).”

BUFFALO, NY - February 9, 2024 – A new research perspective was recently published in Oncoscience (Volume 11) on February 7, 2024, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed

“Diagnosed with numerous metastases of lung cancer in my brain in January 2023, I felt compelled to accomplish a mission.”

BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”

“In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I... continue reading >>